U.S. Federal Trade Commission: FTC requires sale of generic cancer pain drug and muscle relaxant as conditions of Teva’s $6.8 billion acquisition of Cephalon
MLex Summary: The Federal Trade Commission has announced the approval of Teva's proposed purchase of Cephalon, conditioned upon the sale of the generic cancer pain drug to the branded drug Actiq...To view the full article, register now.
Already a subscriber? Click here to view full article